血管痴呆症中的BDNF信号及其对脑血管功能障碍,突触可塑性和胆固醇系统异常的影响
1Department of Anatomy, Chonnam National University Medical School, Hwasun, Korea.
Journal of lipid and atherosclerosis
|June 3, 2024
概括
低血清水平的大脑衍生神经营养因子 (BDNF) 与血管痴呆症 (VaD) 有关. 了解BDNF的理解
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物化学 生化学
背景情况:
- 血管性痴呆 (VaD) 是导致痴呆的第二大原因,其特征是认知缺陷和神经病理变化.
- 大脑衍生神经营养因子 (BDNF) 在神经元生存,突触可塑性和认知功能中起着至关重要的作用.
- 在VaD患者中观察到血清和脑脊液BDNF水平降低,这表明它与疾病有关.
研究的目的:
- 审查目前对BDNF信号传递在血管痴呆症神经病理学中的作用的理解.
- 探索BDNF如何影响VaD中的关键病理过程,包括脑血管功能障碍,突触障碍和胆固醇缺陷.
主要方法:
- 对BDNF和血管痴呆症现有研究的文献综述.
- 对研究BDNF水平和VAD患者和模型中的信号通路的研究分析.
主要成果:
- 与健康个体相比,患有VaD的患者表现出明显较低的血清BDNF水平.
- 确定BDNF缺乏是VaD的一个关键指标.
- 在VaD.中,BDNF信号与大脑血管功能障碍,突触障碍和胆固醇系统异常有关.
结论:
- 在血管痴呆症的神经病理学中,BDNF起着至关重要的作用.
- BDNF水平作为VaD的一个重要的生物标志物.
- 准BDNF信号通路可能为预防和治疗VaD提供治疗策略.
相关概念视频
Notch Signaling Pathway
4.2K
The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
4.2K
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
The Blood-brain Barrier
47.2K
Overview
47.2K
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120


